Robinson, CarrieHarrison, BethLigon, AzraDong, FeiMaffeis, ValeriaMatulonis, UrsulaNucci, MarisaKolin, David L.2022-08-312020-10-19Robinson, Carrie L, Beth T Harrison, Azra H Ligon, Fei Dong, Valeria Maffeis, Ursula Matulonis, Marisa R Nucci, and David L Kolin. 2021. “Detection of ERBB2 Amplification in Uterine Serous Carcinoma by Next-Generation Sequencing: An Approach Highly Concordant with Standard Assays.” Modern Pathology 34 (3): 603–12.0893-39521530-0285https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37373119Uterine serous carcinoma is an aggressive subtype of endometrial cancer that accounts for fewer than 10% of endometrial carcinomas but is responsible for about half of deaths. A subset of cases has HER2 overexpression secondary to ERBB2 gene amplification, and these patients may benefit from anti-HER2 therapies, such as trastuzumab. HER2 protein overexpression is currently assessed by immunohistochemistry (IHC) and ERBB2 gene amplification by fluorescence in situ hybridization (FISH). Targeted next-generation sequencing (NGS) is increasingly used to routinely identify predictive and prognostic molecular abnormalities in endometrial carcinoma. To investigate the ability of a targeted NGS panel to detect ERBB2 amplification, we identified cases of uterine serous carcinoma (n=93) and compared HER2 expression by IHC and copy number assessed by FISH with copy number status assessed by NGS. ERBB2 copy number status using a combination of IHC and FISH was interpreted using the 2018 ASCO/CAP guidelines for breast carcinoma. ERBB2 amplification by NGS was determined by the relative number of reads mapping to ERBB2 in tumor DNA compared to control non-neoplastic DNA. Cases with copy number ≥6 were considered amplified and copy number <6 were non-amplified. By IHC, 70 specimens were classified as negative (0 or 1+), 19 were classified as equivocal (2+), and 4 were classified as positive (3+). Using combined IHC/FISH, ERBB2 amplification was observed in 8 of 93 cases (9%). NGS identified the same 8 cases with copy number ≥6; all 85 others had copy number <6. In this series, NGS had 100% concordance with combined IHC/FISH in identifying ERBB2 amplification. NGS is highly accurate in detecting ERBB2 amplification in uterine serous carcinoma and provides an alternative to measurement by IHC and FISH.en-USPathology and Forensic MedicineJournal Article2022-08-3110.1038/s41379-020-00695-5